November 9, 2004
Cougar Biotechnology Appoints Vice President of Clinical Research and Development
Los Angeles, CA, November 9, 2004 - Cougar Biotechnology, Inc, a privately held
biotechnology company, today announced the appointment of Gloria Lee, M.D, Ph.D. as Vice President
of Clinical Research and Development. Dr. Lee brings 12 years of oncology clinical development
to her role at Cougar. She will be responsible for the clinical development of Cougar's portfolio
of drugs in development, including CB7630 and CB3304.
"We are pleased to have someone of Gloria’s caliber join Cougar at this important stage of the
Company's development. Gloria's extensive clinical development experience coupled with her
practical knowledge as a board certified medical oncologist will be tremendously useful to Cougar"
said Dr. Arie Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology.
Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added "Gloria
brings to Cougar a wealth of clinical development expertise in the field of oncology that will be
very valuable in guiding the direction of Cougar’s clinical development program."
Dr. Lee joins Cougar from Chiron Corporation, where she held the position of Senior Director,
Clinical Development-Oncology since 2003. Prior to Chiron, Dr. Lee was Senior Therapeutic Expert
in Oncology at Hoffman La Roche from 1999 to 2003. Dr Lee also served in a variety of clinical
development positions at Rhone Poulenc Rorer (now Aventis) from 1994 through 1999 including the
position of Associate Director of Medical Affairs where Dr. Lee was responsible for the clinical
development of the anticancer drug Taxotere in breast cancer. Dr. Lee is a board certified medical
oncologist and holds an M.D, from The University of Miami School of Medicine and a Ph.D. in
molecular biology from Columbia University.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to
in-license and develop early clinical stage drugs, with a specific focus on the field of oncology.
Cougar’s oncology portfolio includes CB7630, which has completed Phase I clinical trials in prostate
cancer and CB3304 which is currently being tested in a Phase I trial in non-Hodgkin's lymphoma.
Further information about Cougar Biotechnology can be found at
www.cougarbiotechnology.com.
Contact
Alan H. Auerbach, Cougar Biotechnology, Inc.
+1 310 443 4209
ahauerbach@cougarbiotechnology.com
|
Dedicated to Innovative Treatments...
|
|
